A comprehensive view of merck & co. inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Merck signs licensing deal for Sichuan Kelun Pharmaceutical’s oncology program for areas outside of China, Hong Kong, Macao, Taiwan; deal worth US$1.4B and may relate to experimental drugs SKB264 or A166 currently in Phase 2 testing in China
Published: May 20, 2022 by SeeNews Pharmaceuticals
Athenex and Merck to collaborate in expanded Phase 1 clinical trial to evaluate oral Oraxol paclitaxel and injectable Keytruda pembrolizumab in patients with non-small cell lung cancer; expansion cohort actively recruiting 50 patients for study
Published: May 17, 2022 by GlobeNewswire
Merck reports Q1 GAAP net income up 57% at US$4.3B, with global sales up 50% to US$15.9B; sales growth favorably impacted by COVID-19 recovery as pharmaceutical sales increased 53% to US$14.1B, animal health sales up 4% at US$1.5B
Published: April 29, 2022 by Business Wire
Most Rite Aid locations now offer prescription COVID-19 oral medications, including Pfizer’s Paxlovid, Merck’s Molnupiravir; treatments available to those who test positive, are at high risk for severe COVID-19, are within five days of symptom onset
Published: April 27, 2022 by Business Wire
Merck stops Phase 3 trial of injectable Keytruda, Lynparza combination to treat metastatic castration-resistant prostate cancer; analysis shows drug combo did not show benefit to survival compared with abiraterone acetate or enzalutamide
Published: April 04, 2022 by BZ Briefs Pharma

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count